Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

y historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the potency, safety and tolerability profile of ANA598 seen to date, which may not be duplicated in future cohorts at higher doses or future clinical studies of longer duration; (ii) the preliminary indications of antiviral activity with ANA773 and next steps for the program; (iii) the potential for ANA598 and ANA773 to become important parts of future combination regimens to treat HCV patients; (iv) the ability of ANA598 to be ready for Phase II studies in mid-2009; and (v) expectations regarding the timing of receiving data. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... (PRWEB) December 26, 2014 India Network ... insurance in the USA, announced today a new version ... members in choosing the right plan for their visiting ... complexity out of the selection process when choosing an ... age group with only a few clicks. Many elderly ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... advertising helps reduce adult smoking, according to a study by ... Health Research and Policy -- but some ads may be ... to a variety of anti-smoking messages on television. However, no ... various sponsors, impact adult smoking behaviors, or on how the ...
... Anaesthetists have identified a major shortfall in funding for emergency ... to establish a more accurate picture of outcomes and costs. ... suggest a shortfall of 300 million per year for emergency ... care. The study also found that emergency laparotomy, ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, April ... the American Heart Association says no convincing evidence exists linking ... there strong evidence that treating gum disease can reduce your ... For more than 100 years, it was said that gum, ...
... Cancer Agency and University of British Columbia have identified ... the disease is diagnosed and form the basis of ... 10 completely new categories based on the genetic fingerprint ... much-needed insight into breast cancer biology, allowing doctors to ...
... and quality-of-life issues should be considered essential elements of ... point of breast cancer diagnosis. However, for women suffering ... other medically underserved areas around the world, this fundamental ... To address these issues, many of the world,s ...
Cached Medicine News:Health News:Anti-tobacco TV ads help adults stop smoking, study finds 2Health News:Study reveals major funding shortfall and high death rates for emergency laparotomy 2Health News:Study reveals major funding shortfall and high death rates for emergency laparotomy 3Health News:Speed and ecstasy associated with depression in teenagers 2Health News:No Proof That Gum Disease Causes Heart Disease, Experts Say 2Health News:No Proof That Gum Disease Causes Heart Disease, Experts Say 3Health News:Scientists rewrite rulebook on breast cancer in landmark global study 2Health News:Scientists rewrite rulebook on breast cancer in landmark global study 3Health News:International breast health global summit will focus on supportive care and quality of life 2Health News:International breast health global summit will focus on supportive care and quality of life 3
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014 Apnea ... expanded corporate offices in Aliso Viejo ... that due to the tremendous growth and worldwide expansion, ... Sales of patented SnoreRx, the anti snore cure have ... He said, "We are now in 23 countries ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... LEUVEN, Belgium, June 25 , ... for the,Non-Surgical Treatment of Eye Disease With No Reported Safety ... THR), a biotechnology company,focused on the discovery and development of ... that its lead product,microplasmin, which is in Phase III trials ...
... personalized chemotherapy can improve cure rate and avoid the ... , , MEMPHIS, Tenn., June 24 ... treated using a carefully personalized chemotherapy regimen without cranial ... found. Such radiation of the brain was once a ...
Cached Medicine Technology:ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 2Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 3Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 4
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight....
3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: